Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inmolecule NanotechFRA:DC0 5 WACC % is Data Outdated as of Sep. 17, 2026. GuruFocus rates FRA:DC0 with a GF Score™ of 5/100. The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, Inmolecule Nanotech ranks better than 59.07% on this metric.
As of today (2026-09-17), Inmolecule Nanotech's weighted average cost of capital is Data Outdated%. Inmolecule Nanotech's ROIC % is -2.01% (calculated using TTM income statement data).
Inmolecule Nanotech generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
For a comprehensive WACC calculation, please access the WACC Calculator.
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Inmolecule Nanotech's weighted average cost of capital is Data Outdated%. Inmolecule Nanotech's ROIC % is -2.01% (calculated using TTM income statement data).
Inmolecule Nanotech generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
Be Aware
1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.
2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.
3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
Related Terms
Inmolecule Nanotech WACC % Historical Data
* Premium members only.
The historical data trend for Inmolecule Nanotech's WACC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inmolecule Nanotech WACC % Chart
Inmolecule Nanotech Annual Data
Trend
Dec23
Dec24
WACC %
0.00
0.00
Inmolecule Nanotech Quarterly Data
Dec23
Dec24
WACC %
0.00
0.00
FRA:DC0 vs VRTX, REGN, MRNA: WACC % Comparison
For the Biotechnology subindustry, Inmolecule Nanotech's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inmolecule Nanotech WACC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inmolecule Nanotech's WACC % distribution charts can be found below:
* The bar in red indicates where Inmolecule Nanotech's WACC % falls into.
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
Inmolecule Nanotech (FRA:DC0) has a WACC % of Data Outdated as of Sep. 17, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Inmolecule Nanotech and its competitors. Over the past decade, Inmolecule Nanotech's WACC % has ranged from 0.57 to 8.81. According to the industry distribution chart, Inmolecule Nanotech ranks #580 out of 1417 companies in the Biotechnology industry, placing it in the top 40.9%.
Is Inmolecule Nanotech's WACC % too high?
Inmolecule Nanotech's current WACC % is Data Outdated. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 8.81. Based on the distribution chart, Inmolecule Nanotech ranks #580 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Inmolecule Nanotech has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Inmolecule Nanotech's WACC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Inmolecule Nanotech ranks #580 out of 1417 companies for WACC %. This puts Inmolecule Nanotech in the upper half of its industry. The industry median WACC % is 10.21. Historically, Inmolecule Nanotech's own WACC % has ranged from 0.57 to 8.81 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 10.21, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Inmolecule Nanotech and its competitors. For the Biotechnology industry, the median WACC % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inmolecule Nanotech's current WACC % is Data Outdated. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inmolecule Nanotech stock overvalued right now?
Inmolecule Nanotech (FRA:DC0) has a current WACC % of Data Outdated. The current WACC % is Data Outdated. Inmolecule Nanotech's overall GF Score™ is 5/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Inmolecule Nanotech (FRA:DC0), the current WACC % is Data Outdated as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DC0 has been successfully added to your 
